Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Blockbuster drug bows out.

Ledford H.

Nature. 2011 Nov 29;480(7375):16-7. doi: 10.1038/480016a. No abstract available. Erratum in: Nature. 2011 Dec 22;480(7378):425.

PMID:
22129701
2.

Lipitor goes generic: business as usual or more big business?

Gill L, Santa J, Peter DL, Keehn J.

Ann Intern Med. 2012 Jun 19;156(12):892-3, W313. doi: 10.7326/0003-4819-156-12-201206190-00420. No abstract available.

PMID:
22711082
3.

Lessons from Lipitor and the broken blockbuster drug model.

The Lancet.

Lancet. 2011 Dec 10;378(9808):1976. doi: 10.1016/S0140-6736(11)61858-8. No abstract available.

PMID:
22153189
4.

Generic atorvastatin and health care costs.

Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM.

N Engl J Med. 2012 Jan 19;366(3):201-4. doi: 10.1056/NEJMp1113112. Epub 2011 Dec 7. No abstract available.

5.

[Pfizer: TLV decision about antilipemic agents is founded on wrong basis].

Brun J, Ohlsson-Onerud A, Sörensen N.

Lakartidningen. 2009 Apr 22-28;106(17):1193-4; discussion 1194. Swedish. No abstract available.

PMID:
19530431
6.

Are we living in the end of the blockbuster drug era?

Debnath B, Al-Mawsawi LQ, Neamati N.

Drug News Perspect. 2010 Dec;23(10):670-84. doi: 10.1358/dnp.2010.23.10.1506088. Review.

PMID:
21180653
7.

Indian biogenerics industry emerges.

Jayaraman KS.

Nat Biotechnol. 2003 Oct;21(10):1115-6. No abstract available.

PMID:
14520378
8.

The right pill for growth. The high cost of developing blockbuster drugs forces big makers into bigger mergers.

Fischer JS.

US News World Rep. 1999 Nov 15;127(19):56. No abstract available.

PMID:
10623304
9.

Reinventing an industry.

Mandavilli A.

Nature. 2007 Jan 11;445(7124):138-9. No abstract available.

PMID:
17215817
10.

Generic atorvastatin and health care costs.

Kennally WC 3rd.

N Engl J Med. 2012 Apr 12;366(15):1451; author reply 1451. doi: 10.1056/NEJMc1202104#SA1. No abstract available.

PMID:
22494136
11.

Overcoming the obstacles in the pharma/biotech industry: 2008 update.

Graul AI, Revel L, Rosa E, Cruces E.

Drug News Perspect. 2009 Jan-Feb;22(1):39-51. doi: 10.1358/dnp.2009.22.1.1303817.

PMID:
19209298
12.
13.

Court refuses to hurry generic Lipitor decision.

Harrison C.

Nat Rev Drug Discov. 2011 Jun;10(6):406-7. doi: 10.1038/nrd3476. No abstract available.

PMID:
21629283
14.

Handle with care.

Macilwain C.

Nature. 2006 Apr 20;440(7087):990-1. No abstract available.

PMID:
16625170
15.

International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.

Kuhrt K, Chace-Ortiz M.

IDrugs. 2009 Dec;12(12):760-4.

PMID:
19943217
16.

Overcoming the challenges in the pharma/biotech industry.

Graul AI, Prous JR.

Drug News Perspect. 2007 Jan-Feb;20(1):57-68.

PMID:
17332900
17.

The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

Lindsley CW.

ACS Chem Neurosci. 2010 Jun 16;1(6):407-8. doi: 10.1021/cn1000556. No abstract available. Erratum in: ACS Chem Neurosci. 2013 Oct 16;4(10):1414.

18.

Betting on biogenerics.

Dove A.

Nat Biotechnol. 2001 Feb;19(2):117-20. No abstract available.

PMID:
11175723
19.

Market watch: Sales of biologics to show robust growth through to 2013.

Goodman M.

Nat Rev Drug Discov. 2009 Nov;8(11):837. doi: 10.1038/nrd3040. No abstract available.

PMID:
19876035
20.

Supplemental Content

Support Center